Drugs & Treatments

Clinical Benefit of Docetaxel or Enzalutamide After Progression on First-Line Abiraterone and Prednisone in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) *

Abiraterone acetate (AA) or Zytiga has demonstrated a survival benefit in the pre-chemotherapy setting for men with advanced prostate cancer that has become castrate resistant (mCRPC). As a result it is in widespread clinical use in the United States prior to the use of chemotherapy with docetaxel. Since its FDA approval post chemotherapy there has [...]

By Malecare|2017-10-19T10:48:05-04:00August 20th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Cross Resistance, Drugs & Treatments, enzalutamide, Uncategorized, Understanding APC, Xtandi|0 Comments

Efficacy of Combined Androgen Blockade with Zoledronic Acid *

It is known that Zoledronic acid (ZA) reduces the risk of developing skeletal-related events (SRE) which are caused by bone metastasis in prostate cancer (PCa). ZA also improves the quality of life (QOL). ZA has become a standard supportive therapy for men with prostate cancer who have bone metastasis. The big unknown is when should [...]

By Malecare|2017-10-19T10:48:05-04:00August 13th, 2014|ADT, Advanced Prostate Cancer, CAB, Combination Therapy, Drugs & Treatments, Uncategorized, Understanding APC|0 Comments

Study Shows That The Immune Responses Is Enhanced and Sustained When Provenge Is Given After Androgen Deprivation Therapy in Biochemically-Recurrent Prostate Cancer

Last April there was some preliminary data from the long-term Phase II STAND study presented at 29th Annual European Association of Urology (EAU) Congress that showed that sipuleucel-T (Provenge) when given after the start of androgen deprivation therapy (ADT) seemed to enhance and sustain the immune response in men with a biochemical failure (PSA only) [...]

By Malecare|2017-10-19T10:48:06-04:00August 12th, 2014|ADT, Advanced Prostate Cancer, Bio Chemical Recurrence, Drugs & Treatments, General Information, Provenge, survival, Uncategorized, Understanding APC|2 Comments

Complementary and Alternative Medicine with Chemotherapy

The following was written and posted by Paul Edwards to the Advanced Prostate Cancer Online Support Group: The March 2014 issue of the Asia-Pacific Journal of Clinical Oncology published an article “Why do some cancer patients receiving chemotherapy choose to take complementary and alternative medicines and what are the risks?” by authors from University of Queensland [...]

By Malecare|2017-10-19T10:48:06-04:00August 6th, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, supplements, Uncategorized|0 Comments

Can Chemotherapy (Docetaxel) Be Enhanced By Zoledronic Acid Pretreatment in Resistant Prostate Cancer Cells *

Docetaxel is the only globally approved first-line chemotherapy for the treatment of castrate resistant prostate cancer. Yhe universal truth is that all men taking docetaxel will become refractory to the treatment. Zoledronic acid (ZA) is the most commonly used member of nitrogen-containing bisphosphonate family. By itself it has anti-tumor activity, including in prostate cancer. In [...]

By Malecare|2014-08-05T14:08:36-04:00August 5th, 2014|Advanced Prostate Cancer, ASCO, bisphosphonates, Chemo Therapy, Chemo Therapy Failure, Combination Therapy, Drugs & Treatments, Research, Uncategorized, Understanding APC, Zometa|0 Comments

Drug Abuse Disorders Negatively Impact Advanced Prostate Cancer Treatment Results

Researchers have reported ahead of print that substance use disorders may adversely affect outcomes in men with advanced prostate cancer This conclusion was drawn from a very large study of 14,277 men with advanced prostate cancer. The study found that men with advanced prostate cancer along with a substance abuse disorder were 2.3 times more [...]

By Malecare|2014-08-02T10:29:07-04:00August 2nd, 2014|Advanced Prostate Cancer, Drugs & Treatments, Research, Uncategorized, Understanding APC|3 Comments

British Men Who Have Had Abiraterone Will Not Get Enzalutamide Despite Its Life Extending Abilities

British Men Who Have Had Abiraterone Will Not Get Enzalutamide Despite Its Life Extending Ability Our brothers in England hit a major snag last week as NHS placed a burdensome restriction on the use of enzalutamide (Xtandi) for men with advanced prostate cancer who have already had abiraterone (Zytiga). Because of this ridiculous decision thousands [...]

By Malecare|2014-07-29T16:01:54-04:00July 29th, 2014|Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, NICE, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Xtandi, Zytiga|0 Comments

What are the Clinical implications of Chemotherapy for Men with Advanced Prostate Cancer Under the Age of 60 years?

Yesterday’s post was about the use of chemotherapy (with docetaxel) for the treatment of men with advanced prostate cancer who were 80 years old or older. Today’s post is about the use of chemotherapy in men 60 years or younger. The research for both of these posts was performed by the same team of scientists [...]

By Malecare|2017-10-19T10:48:07-04:00July 22nd, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, Research, survival, Uncategorized, Understanding APC|0 Comments

Should Men Over the Age of 80 Years Consider Chemotherapy? *

Chemotherapy (chemo with docetaxel) has a reputation for being a difficult therapy loaded with many side effects. I believe that this reputation is overblown given that all of our new non-chemotherapies (other than Provenge) come with their own list of significant side effects. However, its reputation is in the minds of many, so men who [...]

By Malecare|2017-10-19T10:48:07-04:00July 21st, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, Research, Uncategorized, Understanding APC|1 Comment

Predicting Resistance to Enzalutamide and Abiraterone in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC).*

In yesterday's post I wrote about the possibility of looking for the presence of the splice variant ARV7 to determine if you would be resistant to enzalutamide (Xtandi). Today I am going to expand on this issue and discuss an additional study that demonstrated that the presence of ARV7 in circulating tumor cells not only [...]

By Malecare|2017-10-19T10:48:07-04:00July 16th, 2014|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Drugs & Treatments, enzalutamide, General Information, ipilimumab, Research, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments